Aortic Stenosis -The Unmet Need Simon Ray University Hospitals of South Manchester ACI 2009.

Slides:



Advertisements
Similar presentations
Socioeconomic Inequalities in Health Among Canadian Women with Heart Disease Arlene S. Bierman, M.D., M.S Ontario Womens Health Council Chair in Womens.
Advertisements

UK Renal Registry 15th Annual Report Figure One year death rate per 1,000 patient years by UK country and age group for prevalent dialysis.
” سبحانك لا علم لنا إلا ما علمتنا إنك أنت العليم الحكيم “
Epidemiology of Peripheral Vascular Disease Sohail Ahmed School of Population and Health Sciences.
Bridget Dillon February 11,  Cardiovascular disease affects the heart and circulatory system. It is often a result of blockages of blood vessels.
UK Renal Registry 16th Annual Report Figure 5.1. Flow chart showing number of patients included in the various analyses.
Alcohol-Related Harm and Unmet Need Amongst Older Drinkers S Wadd, R Driver, D Forrester.
Percutaneous mitral valve repair using the MitraClip® device (e-valve)
Prospettive nell’utilizzo delle valvole percutanee: oltre la stenosi valvolare aortica degenerativa Luca Testa, MD, PhD Istituto Clinico S. Ambrogio Milano.
Lessons from TAVR Randomized Trials and Registries E Murat Tuzcu, MD Professor of Medicine Cleveland Clinic Financial disclosures: None PARTNER Executive.
Department of Cardiothoracic Surgery St. George’s Healthcare NHS Trust St. George’s University of London.
Section 1: CKD Epidemiology. The Problem Chronic Kidney Disease is an epidemic worldwide –Growth 6-8% per annum of dialysis patients Accumulating data.
Chronic kidney disease Mr James Hollinshead Public Health Analyst East Midlands Public Health Observatory (EMPHO) UK Renal Registry 2011 Annual Audit Meeting.
Two Cardiac Centres Are Better Than One Early Outcomes of the First 75 Open Heart Surgeries At Port of Spain General Hospital Randolph Rawlins M.B.B.S.,
Burden of Musculoskeletal Diseases, Third Edition Data to address goals of the Global Alliance for Musculoskeletal Health History declared United.
Institute Institute of Cardiovascular Diseases Prof Dr George IM Georgescu, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania WC. Hsieh,
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
What Have We Learned From The UK TAVI Registry? Simon Ray UHSM Manchester Academic Health Sciences Centre.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.
The Power of Innovation and Collaboration: Securing the Future of General Practice Why GPs need to do something different Dr Mike Bewick NHS England -
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Maria N. Gamaletsou 1,2, David Denning 1, and Nikolaos V. Sipsas 2 1 The National Aspergillosis Centre, University Hospital of South Manchester and The.
Trancatheter Aortic Valve Implantation (TAVI)
Martin B. Leon, MD on behalf of the PARTNER Investigators TCT 2010; Washington, DC; September 23, 2010 Transcatheter Aortic Valve Implantation in Inoperable.
UK Renal Registry 15th Annual Report Figure D.1. 95% confidence limits for incidence of 108 pmp for population size 80,000–800,000.
BCIS Autumn Meeting, Crewe, September 2008 Transcatheter Aortic Valve Intervention: How do we take it forward in the UK? Mark de Belder President, British.
The United Kingdom.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Asymptomatic mitral regurgitation When should you operate? Ben Bridgewater Cardiac surgeon and lead clinician, UHSM, Manchester Honorary Reader, Manchester.
Improvements needed in the care of people living with Dementia.
Greater New York Geriatric Cardiology Consortium: Valve Disease in Older Adults Allan Schwartz, MD Columbia University Medical Center New York Presbyterian.
Patients the Surgeon Should Refer for TAVR
Extending the Boundaries of TAVR: Future Directions
O122 Tavi Karlsruhe (Tavik) – A Comparison Of Minimal Invasive And Surgical Aortic Valve Replacement In Patients With Severe Symptomatic Aortic Stenosis.
Anita W. Asgar MD, FRCPC, FACC Montreal Heart Institute
Are we ready to perform TAVI in Intermediate Risk Patients?
Updates From NOTION: The First All-Comer TAVR Trial
Adherence to the Labeling
From: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve ReplacementA Systematic Review and Meta-analysis Ann Intern Med. 2016;165(5):
The Spanish Data Bank PEGASO M. Martínez-Sellés
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
University of Pennsylvania
5th Meeting on Acute Cardiac Care and Emergency Medicine, 2016 Vilnius
Giuseppe Tarantini MD, PhD
Longevity of transcatheter and surgical bioprosthetic aortic valves in patients with severe aortic stenosis and lower surgical risk Lars Sondergaard,
Niv Ad, MD Chief, Cardiac Surgery Professor of Surgery, VCU
Michael Mack, M.D. Dallas, TX February 21, 2010
UK Renal Registry 9th Annual Report 2006
Hisato Takagi, MD, PhD, Takuya Umemoto, MD, PhD 
Is Open Heart Surgery Too Risky For You? Opt for a Minimally Invasive Procedure.
The Ever-Expanding Patient Pool for TAVR:
Update in Cardiac and Thoracic Surgery
Reply The Annals of Thoracic Surgery
Coronary Revascularization and TAVR
Coronary Artery Surgery
Robert A. Meguid, MD, MPH, Benjamin S. Brooke, MD, Bruce A
Nat. Rev. Cardiol. doi: /nrcardio
Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.
Aortic valve replacement in patients with mild or moderate aortic stenosis and coronary bypass surgery  Jeremy J. Pereira, MB, Krzysztof Balaban, MD,
UK Renal Registry 15th Annual Report
Operative mortality rates for intact and ruptured abdominal aortic aneurysms in Michigan: An eleven-year statewide experience  Dolores J. Katz, MPH, James.
Hisato Takagi, MD, PhD, Takuya Umemoto, MD, PhD 
UK Renal Registry 10th Annual Report 2007
UK Renal Registry 14th Annual Report
Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005  Scott D. Barnett, PhD,
Thomas A. Treibel et al. JACC 2018;71:
UK Renal Registry 12th Annual Report
Commentary: When a choice is not an echo
Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.
Presentation transcript:

Aortic Stenosis -The Unmet Need Simon Ray University Hospitals of South Manchester ACI 2009

NO CONFLICT OF INTEREST TO DECLARE ACI 2009

Unmet Need – Lack of Data No epidemiological data for the prevalence of valve disease in the UK No UK data on the number of patients with known symptomatic aortic stenosis not referred for surgery No UK data on the number of patients referred for surgery but not operated ACI 2009

Unmet Need – US Data Prevalence of moderate to severe aortic valve disease in the US population > 75 years 2.8% English population > 75 years about 3.9M About 110K individuals in England >75 years with moderate to severe AS About 1200 AVR performed annually >75years About 1.1% of affected population operated annually ACI 2009

Unmet Need – Euro Heart Euro Heart Survey –About 1/3 older or comorbid patients not referred for surgery For age >75 ‘surgical rejects’ alone: –600 TAVI candidates per year in England Assume some switch of ‘high risk’ > 75 patients to TAVI: –10%; 720 per year –20%; 840 per year ACI 2009

Unmet Need – SCTS Data SCTS data for high risk surgery in the UK –About 1500 per year over 80 or Euroscore > 10 –Mortality about 10% Assume 1/3 not referred and suitable for TAVI: –750 TAVI for UK Assume some switch of ‘high risk’ to TAVI –10%; 900 TAVI per year for the UK –20%; 1050 TAVI per year for the UK ACI 2009

Possible Demand Relatively conservative estimates: –About 1000 TAVI per annum for the UK –About 900 for England and Wales –About 16/million population Does not take into account the impact of possible trials of lower risk patients ACI 2009